Ann: Botanix Partners with Telehealth Provider UpScriptHealth, page-13

I should have qualified that I think the next report on Kaken royalties payable to BOT, may see a bit of improvement to the SP. Not that the dollar figure will be huge for BOT, but rather it will be indicative of the uptake of the product in Japan and the significant market share increase there of SB (sadly, BOT only get very little of that in the royalties they receive from Kaken).

2024 will be a replay of 2023 in the leadup to approval, IMO. Starting February 2023, the SP went from 5c to 20c in the 7 months leading up to the anticipated approval date. Why wasn't it 20c 7 months before approval - simply put, there was no need to have your money parked there as you weren't earning on it. I expect exactly the same trend this time around leading up to approval, although possibly even higher this time because we're starting the runup at a higher base (12c) and approval is certain this time, whereas there was a little room for doubt before (i.e. FDA hadn't accepted the science - now they have).